Analysis of remdesivir COVID-19 trials posts encouraging resultsIn a comparative analysis published late last week in Clinical Infectious Diseases, the antiviral drug remdesivir was linked to significantly greater recovery and a 62% lower death rate by day 14 versus standard treatment in hospitalized adults with severe COVID-19.Researchers used data from 298 participants in an ongoing phase 3 trial of remdesivir at 45 international sites, as well as retrospective data from an ongoing real-world longitudinal study of 816 patients given standard treatment at 16 international sites.Patients in the remdesivir group were randomly assigned to receive standard treatment plus 200 milligrams (mg) of remdesivir on day 1, followed by either 4 or 8